Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.45 |
| ▸ | PPARG | P37231 | 8/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.36 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.36 |
| ▸ | MPC2 | O95563 | 1/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1130749 | 0.90 | PPARG (0.47) | PTPN1PPARGMAPTCYP2C9POLB | |
| SCHEMBL8857154 | 0.88 | PPARG (0.43) | PPARGMAPTCYP2C9MCL1KDM4E | |
| SCHEMBL8309388 | 0.88 | PPARG (0.44) | PPARGMAPTCYP2C9MCL1KDM4E | |
| SCHEMBL8405115 | 0.83 | MTNR1A (0.38) | PTPN1PPARG | |
| SCHEMBL8405118 | 0.83 | MTNR1A (0.38) | PTPN1PPARG | |
| SCHEMBL8304179 | 0.81 | MCL1 (0.41) | PPARGMAPTPOLBNPSR1MCL1 | |
| SCHEMBL8306634 | 0.81 | CTRB1 (0.41) | NPSR1MEN1KMT2A | |
| SCHEMBL27516237 | 0.78 | MAPT (0.51) | PPARGMAPTCYP2C9LMNAPOLB | |
| SCHEMBL7834863 | 0.75 | KDM4E (0.34) | PPARGMAPTMCL1KDM4EMEN1 | |
| SCHEMBL8668616 | 0.75 | PPARG (0.34) | PPARGMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1607385-A1 | Intermediates for the synthesis of benzimidazole compounds and process for the preparation thereof | Sankyo Company Limited (JP) | 2005-12-21 | — | — | EP | disclosed |
| US-6753347-B2 | CONDENSATION OF AMINE DERIVATIVE WITH CARBOXYLIC ACID DERIVATIVES TO AFFORD INTERMEDIATE COMPOUND, FOLLOWED BY CYCLIZATION OF INTERMEDIATE COMPOUND IN PRESENCE OF ACID; HYOPOGLYCEMIC ACTION | SANKYO COMPANY, LIMITED (JP) | 2004-06-22 | — | — | US | disclosed |
| US-20030199580-A1 | Intermediates for the synthesis of benzimidazole derivatives and a process for the preparation thereof | SANKYO COMPANY, LIMITED (JP) | 2003-10-23 | — | — | US | disclosed |
| US-6569877-B2 | Benzimidazolyl phenyl anticancer agents | SANKYO COMPANY, LIMITED (JP) | 2003-05-27 | — | — | US | disclosed |
| US-6525220-B2 | Having hypoglycemic action | SANKYO COMPANY, LIMITED (JP) | 2003-02-25 | — | — | US | disclosed |
| US-20030008907-A1 | Intermediates for the synthesis of benzimidazole derivatives and a process for the preparation thereof | SANKYO COMPANY, LIMITED (JP) | 2003-01-09 | — | — | US | disclosed |
| US-20020137776-A1 | Therapeutic and prophylactic agents for neoplasms | SANKYO COMPANY, LIMITED (JP) | 2002-09-26 | — | — | US | disclosed |
| EP-1197211-A1 | PREVENTIVE AND THERAPEUTIC AGENTS FOR CANCER | Sankyo Company, Limited (JP) | 2002-04-17 | — | — | EP | disclosed |
| EP-1191019-A1 | INTERMEDIATES FOR THE SYNTHESIS OF BENZIMIDAZOLE COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF | Sankyo Company, Limited (JP) | 2002-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137776-A1 | Therapeutic and prophylactic agents for neoplasms | VHL, TP53, BRCA1 | PTPN1 2768/4885PPARG 1300/4885MAPT 3901/4885 |
| US-20030008907-A1 | Intermediates for the synthesis of benzimidazole derivatives and a process for the preparation thereof | H1-4, H1-3, GCK | PTPN1 4603/4885PPARG 1269/4885MAPT 4674/4885 |
| US-20030199580-A1 | Intermediates for the synthesis of benzimidazole derivatives and a process for the preparation thereof | H1-4, H1-3, GCK | PTPN1 4603/4885PPARG 1269/4885MAPT 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.